Gynecologic and Obstetric Investigation
Original Article
Uterine Activity after Oral Mifepristone Administration in Human Pregnancies beyond 41 Weeks’ GestationFassett M.J. · Wing D.A.Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, Calif., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: September 23, 2006
Accepted: April 20, 2007
Published online: October 02, 2007
Issue release date: March 2008
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Background/Aim: To examine the effect of oral mifepristone on uterine activity in postterm human pregnancies. Methods: As part of a randomized, placebo-controlled trial comparing 200 mg oral mifepristone to placebo for preinduction cervical ripening in women with well-dated pregnancies beyond 41 weeks’ gestation with unfavorable cervices, uterine activity was continuously recorded with external tocodynamometry and contraction frequency tabulated. Results: Ninety-seven women received mifepristone and 83 women received placebo. Uterine activity (uterine contractions/hour) was greater in the mifepristone than in the placebo group between 7 h (8.03 ± 0.48 vs. 5.90 ± 0.39, p = 0.001) and 24 h (8.53 ± 0.68 vs. 6.61 ± 0.46, p = 0.02) after dosing. Conclusion: Oral mifepristone administration to women with pregnancies beyond 41 weeks increases uterine activity in the absence of externally administered uterotonic agents.
© 2007 S. Karger AG, Basel
Related Articles:
References
- Edwards MS: Mifepristone: cervical ripening and induction of labor. Clin Obstet Gynecol 1996;39:469–473.
- Chwalisz K: The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery. Hum Reprod 1994;9:131–161.
- Swahn ML, Bygdeman M: The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 1988;95:126–134.
- Frydman R, Lelaidier C, Baton-Saint-Mleux C, Fernandez H, Vial M, Bourget P: Labor induction at term with mifepristone (RU486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992;80:972–975.
- Haluska GJ, Stanczyk FZ, Cook MJ, Novy MJ: Temporal changes in uterine activity and prostaglandin response to RU486 in rhesus macaques in late gestation. Am J Obstet Gynecol 1987;157:1487–1495.
-
Germain G, Philibert D, Pottier J, Moren M, Baulieu E, Sureau C: Effect of the antiprogesterone agent RU 486 on the natural cycle and gestation in intact cynomolgus monkeys; in Baulieu EE, Segal SJ (eds): The Antiprogestin Steroid RU486 and Human Fertility Control. New York, Plenum Press, 1985, pp 155–167 .
- Giacalone PL, Daures JP, Faure JM, Boulot P, Hedon B, Laffargue F: The effects of mifepristone on uterine sensitivity to oxytocin and fetal heart rate patterns. Eur J Obstet Gynecol Reprod Biol 2001;97:30–34.
- Berkane N, Verstraete L, Uzan S, Boog G, Bernard M: Use of mifepristone to ripen the cervix and induce labor in term pregnancies. Am J Obstet Gynecol 2005;192:114–120.
- Wing DA, Fassett MJ, Mishell DR: Mifepristone for preinduction cervical ripening beyond 41 weeks’ gestation: a randomized controlled trial. Obstet Gynecol 2000;96:543–548.
- Bygdeman M, Swahn ML: Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception 1985;32:45–51.
- Heikinheimo O: Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet 1997;33:7–17.
- Heikinheimo O, Kekkonen R, Lahteenmaki P: The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003;68:421–426.
- Elliott CL, Brennand JE, Calder AA: The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet Gynecol 1998;92:804–809.
Article / Publication Details
Received: September 23, 2006
Accepted: April 20, 2007
Published online: October 02, 2007
Issue release date: March 2008
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
